Clinical Trial Update: Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) [Phase 2]

View source ↗

Summary

This is a Phase 2 study of ridaforolimus (MK-8669) in taxane-resistant androgen-independent prostate cancer that has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED